Provera pills 500mg, 30pcs

Composition

1 tablet contains:

Active ingredients:

medroxyprogesterone (in the form of acetate) 500 mg.

Auxiliary substances:

corn starch;

magnesium stearate;

MCC;

gelatin;

polyethylene glycol 400;

sodium starch salt;

sodium docusate (85%) with sodium benzoate (15%).

The blister contains 10 tablets.

The package contains 3 blisters.

Pharmacological action

Pharmacodynamics

Progestogen. It has no androgenic and estrogenic activity. Inhibits the secretion of gonadotropin hormones (especially LH). In small doses, it suppresses ovulation. It has an inhibitory effect on changes necessary to prepare the endometrium for implantation of a fertilized egg and increases the viscosity of cervical mucus.

In higher doses, it has an antitumor effect in hormone-sensitive malignant neoplasms. This effect is probably due to the effect on the receptors of steroid hormones and on the pituitary-gonadal system.

Pharmacokinetics

Binding to plasma proteins is 90-95%. Penetrates through the BBB, is excreted in breast milk. It is metabolized in the liver.

T_1/2 is about 30 hours. It is excreted in the bile and urine in the form of metabolites and unchanged.

Indications

For use in gynecology:

• contraception;
• endometriosis.

For use in oncology:

• additional and palliative treatment of recurrent and metastatic endometrial or kidney cancer;
• palliative treatment for hormone-dependent forms of recurrent breast cancer in postmenopausal women;
• prostate carcinoma, some forms of prostate adenoma;
• cancer cachexia in advanced tumors of various localization.

Use during pregnancy and lactation

Contraindicated in pregnancy.

Does not affect lactation. It is excreted in breast milk in a small amount, while negative phenomena in the development of children receiving this milk are not observed.

Contraindications

• Pregnancy;
• hypersensitivity to medroxyprogesterone.

Side effects

From the central nervous system: headache, irritability, sleep disorders, drowsiness, fatigue, depression, dizziness.

From the digestive system: nausea.

Allergic reactions: urticaria, pruritus, rash, anaphylactoid reactions.

From the hematopoietic system: thromboembolic disorders.

From the endocrine system: hypersensitivity of the breast, galactorrhea, erosion and changes in the secretion of the cervix. When used at a dose of 500 mg/day or more, acne, hirsutism, weight gain, and a “moon-shaped” face are possible.

Other: hyperthermia.

Interaction

When used concomitantly with aminoglutetimide, it is possible to reduce the concentration of medroxyprogesterone in blood plasma.

When used concomitantly with drugs that induce the induction of microsomal liver enzymes, it is possible to reduce the contraceptive effect of medroxyprogesterone with parenteral use.

Carbamazepine, griseofulvin, phenobarbital, phenytoin, rifampicin may increase the clearance of progestogens (progestogens).

Progestogens (progestogens) can alter the effectiveness of hypoglycemic medications.

Progestogens (progestogens) can inhibit the metabolism of cyclosporine, which leads to an increase in its concentration in blood plasma and an increased risk of toxicity.

How to take, course of use and dosage

They are set individually, depending on the indications, the stage of the disease, and the treatment regimen.

Special instructions

It is necessary to strictly observe the compliance of the used dosage form of the drug with the indications for use.

Medroxyprogesterone should be used with extreme caution in patients with thrombophlebitis, thromboembolic complications, severe hepatic impairment, and hypercalcemia.

Before using medroxyprogesterone for the treatment of gynecological diseases and contraception, it is necessary to exclude the presence of a tumor of the genitals or mammary glands in the patient.

When conducting pathohistological studies of certain organs and tissues, it is necessary to warn the histologist about previous treatment with progestogens. Against the background of the use of medroxyprogesterone, the results of the following studies may change: determination of the level of gonadotropins; determination of the level of progesterone, cortisol, testosterone (in men), estrogens (in women) in blood plasma; determination of the level of pregnanediol in urine; conducting a test with a sugar load; conducting a test with metapirone.

Form of production

Tablets

Storage conditions

At a temperature of 15-30 °C

Shelf life

5 years

Active ingredient

Medroxyprogesterone

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as prescribed by a doctor, For women

Indications

Prostate Adenoma, Breast Cancer